Flavia Barragan

Title: Flavia Barragan: Innovator in Cancer Research

Introduction

Flavia Barragan is a prominent inventor based in Berlin, Germany. She has made significant contributions to the field of cancer research through her innovative work on peptides that inhibit the function of the Polycomb Repressive Complex 2 (PRC2). Her research focuses on developing novel therapeutic strategies to combat cancer.

Latest Patents

Flavia Barragan holds a patent for her invention titled "Bis-thioether stapled peptides as inhibitors of PRC2 function." This patent describes three novel bisthioether stapled peptides that act as allosteric inhibitors of PRC2's catalytic function. These inhibitors have demonstrated cell permeability, potent activity in physiological conditions, and strong antiproliferative effects on cancer cells. Notably, they target two protein interfaces in PRC2 that are crucial for its proper assembly and histone methyltransferase activity.

Career Highlights

Flavia Barragan is affiliated with The City University of New York, where she continues her research and development efforts. Her work has garnered attention for its potential impact on cancer treatment and understanding the mechanisms of PRC2.

Collaborations

Flavia collaborates with notable colleagues, including Gan Zhang and Guillermo Gerona-Navarro. Their combined expertise enhances the research efforts and contributes to the advancement of cancer therapies.

Conclusion

Flavia Barragan is a trailblazer in the field of cancer research, with her innovative peptides offering new avenues for treatment. Her contributions are paving the way for future advancements in combating cancer effectively.